Jiangsu Hengrui Medicine's (SHA:600276) unit, Fujian Shengdi Pharmaceutical, will conduct clinical trials on hypertension drug after receiving approval from the Chinese drug administrator, according to a Shanghai Stock Exchange filing on Oct. 25.
The pharmaceutical company invested 42.8 million yuan into the research and development of the drug, HRS-9563 injection, the filing said.
Shares of the company rose more than 1% in recent trade.
Price (RMB): ¥48.70, Change: ¥+0.70, Percent Change: +1.46%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments